ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,37%
Bitcoin
65 956,83
-1,20%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nabriva Therapeutics PLC (NBRV)

  7. Nabriva Therapeutics PLC (NBRV) Actualités

NBRV

Nabriva Therapeutics (NBRV)

Nabriva Therapeutics PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NBRV
DateHeureSourceTitreSymboleSociété
25/10/202319h43Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:NBRVNabriva Therapeutics PLC
25/10/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NBRVNabriva Therapeutics PLC
20/10/202303h01Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NBRVNabriva Therapeutics PLC
20/10/202302h22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:NBRVNabriva Therapeutics PLC
31/07/202314h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBRVNabriva Therapeutics PLC
10/07/202323h49Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NBRVNabriva Therapeutics PLC
10/07/202322h01GlobeNewswire Inc.Arbutus Appoints Two New ExecutivesNASDAQ:NBRVNabriva Therapeutics PLC
01/06/202322h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBRVNabriva Therapeutics PLC
22/05/202322h02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NBRVNabriva Therapeutics PLC
15/05/202323h25Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:NBRVNabriva Therapeutics PLC
31/03/202322h30Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:NBRVNabriva Therapeutics PLC
10/01/202323h59Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
06/01/202313h01GlobeNewswire Inc.Nabriva Therapeutics Provides Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
29/11/202212h30TipRanksAnalysts Conflicted on These Healthcare Names: Nabriva (NBRV), Vir Biotechnology (VIR) and Greenwich LifeSciences (GLSI)NASDAQ:NBRVNabriva Therapeutics PLC
28/11/202213h01GlobeNewswire Inc.Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNASDAQ:NBRVNabriva Therapeutics PLC
10/11/202222h01GlobeNewswire Inc.Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
07/11/202213h01GlobeNewswire Inc.Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022NASDAQ:NBRVNabriva Therapeutics PLC
15/09/202213h01GlobeNewswire Inc.Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock SplitNASDAQ:NBRVNabriva Therapeutics PLC
06/09/202213h01GlobeNewswire Inc.Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:NBRVNabriva Therapeutics PLC
12/08/202212h36TipRanksH.C. Wainwright Remains a Hold on Nabriva (NBRV)NASDAQ:NBRVNabriva Therapeutics PLC
11/08/202213h01GlobeNewswire Inc.Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNASDAQ:NBRVNabriva Therapeutics PLC
03/08/202222h01GlobeNewswire Inc.Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
20/07/202222h05GlobeNewswire Inc.Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022NASDAQ:NBRVNabriva Therapeutics PLC
18/07/202215h56Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:NBRVNabriva Therapeutics PLC
18/07/202213h01GlobeNewswire Inc.Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim PharmaceuticalsNASDAQ:NBRVNabriva Therapeutics PLC
29/06/202222h23Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:NBRVNabriva Therapeutics PLC
13/05/202213h01GlobeNewswire Inc.Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:NBRVNabriva Therapeutics PLC
05/05/202222h01GlobeNewswire Inc.Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
05/05/202213h01GlobeNewswire Inc.Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026NASDAQ:NBRVNabriva Therapeutics PLC
02/05/202222h05GlobeNewswire Inc.Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022NASDAQ:NBRVNabriva Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:NBRV

Dernières Valeurs Consultées

EU
PX1
CAC 40
NYSE
KO
Coca Cola
EU
RNO
Renault
EU
VK
Vallourec
NYSE
DIS
Walt Disney
NASDAQ
AMZN
Amazon.com
EU
AI
Air Liquide
EU
ACA
Credit Agricole
EU
LR
Legrand
NYSE
JPM
JP Morgan Chase
EU
CAP
Capgemini
NYSE
NKE
Nike
EU
CS
Axa
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés